A detailed history of Pnc Financial Services Group, Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 1,729 shares of PTGX stock, worth $70,283. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,729
Previous 14 12250.0%
Holding current value
$70,283
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$33.72 - $47.33 $57,829 - $81,170
1,715 Added 12250.0%
1,729 $77,000
Q2 2024

Aug 09, 2024

BUY
$24.66 - $34.8 $345 - $487
14 New
14 $0
Q4 2023

Feb 09, 2024

SELL
$14.05 - $23.44 $1,545 - $2,578
-110 Reduced 95.65%
5 $0
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $1,239 - $2,918
115 New
115 $2,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.